The UCLA Lung Cancer Program is comprised of a multidisciplinary team of experts who are dedicated to the prevention, detection, treatment, and research of lung cancer.
 
Schedule an Appointment
Lung Cancer Home
About Us
Our Expert Team
Our Services
Thoracic Surgery
First Visit for Patients
Patient Education
Clinical Trials
For Referring Physicians
Lung Screening Clinic
Insurance Questions
Map-Directions-Parking
Contact Us
Giving / Donations
Webcasts
Resources
Site Map



Schedule an Appointment

Clinical Trials


Clinical Trials - Lung Cancer Program at UCLA - Los Angeles, California

 

Study Name  

Drug name or type

Disease

PI

Contact

Abound 70+

abraxane + carboplatin

elderly subjects + advanced NSCLC

Goldman

Jenny Strunck (310) 794-3893

Amgen 20070782

Chemotherapy

Anemic NSCLC

Glaspy

Jenny Strunck (310) 794-3893

Amgen 20120249

Denosumab + chemotherapy

Frontline metastatic NSCLC

Glaspy

Jenny Strunck (310) 794-3893

Aromasin

SOC chemo + exemestane (aromatase inhibitor)

Frontline post-menopausal women w/ stage IV NSCLC

Garon

Jenny Strunck (310) 794-3893

Celgene ABI-007-ST-001 Solid Tumors

Azacitidine + chemotherapy

Solid Tumors

Wainberg

Jenny Strunck (310) 794-3893

AstraZeneca D4191C00001 PACIFIC

MEDI4736 (anti-PD-L1)

Stage IIIb NSCLC following CRT

Goldman

Jenny Strunck (310) 794-3893

Checkmate 153

Nivolumab (immunotherapy)

previously treated, adanced or metastatic NSCLC

Garon

Jenny Strunck (310) 794-3893

Clovis CO-1686-019  (TIGER-2)

Rociletinib (EGFR TKI)

Previously treated, EGFRm NSCLC

Goldman

Jenny Strunck (310) 794-3893

Clovis EOS Lucitanib

Lucitanib

Previously treated, FGFR-1 driven NSCLC

Goldman

Jenny Strunck (310) 794-3893

EMD Serono EMR100070-001 Solid Tumor

Avelumab (immunotherapy)

Solid Tumors

Wong

Jenny Strunck (310) 794-3893

Janssen 42756493EDI1001

JNJ-42756493 (pan-FGFR inhibitor)

Advanced or refractory solid tumors or lymphoma

Garon

Jenny Strunck (310) 794-3893

Heat HS110-201 NSCLC

Vaccine trial

Previously treated advanced  NSCLC

Garon

Jenny Strunck (310) 794-3893

Lilly 13Y-MC-JPBJ NSCLC

LY2835219 + anti cancer drug (pemetrexed, gemcitabine, ramucirumab, LY3023414)

Stage IV NSCLC 

Goldman

Jenny Strunck (310) 794-3893

Lilly I3Y-MC-JPBK

Abemaciclib (CDK 4/6 Dual Inhibitor) + SOC vs. Erlotinib + SOC

Previously treated KRASm metastatic NSCLC

Goldman

Jenny Strunck (310) 794-3893

MedImmune CD-ON-MEDI0639-1078 SMLC

MEDI0639 (anti-PD-L1 immunotherapy)

Advanced solid tumors

Goldman

Jenny Strunck (310) 794-3893

Merck MK3475-024-00 (Keynote-024)

Pembrolizomab vs. platinum based chemotherapy

NSCLC w/ high PD-L1 expression

Garon

Jenny Strunck (310) 794-3893

Pfizer B1641003 Solid Tumors

Pf-05082566 (4-1bb agonist) + MK-3475

Previously treated advanced/metastatic solid tumors

Hu-Lieskovan

Jenny Strunck (310) 794-3893

Roche GO29322 Solid Tumors

MPDL3280A + Ipilimumab vs MPDL3280A + Interferon-alpha

Advanced or metastatic solid tumors

Wong

Jenny Strunck (310) 794-3893

Synta 9090-14

Ganetespib (HSP90 inhibitor) + docetaxel vs. docetaxel alone

Advanced Stage IIIB or IV NSCLC

Goldman

Jenny Strunck (310) 794-3893

Threshold TH-CR-415

Pemetrexed + evofosfamide (TH302) vs Pemetrexed + Placebo

Secondline stage IIIB-IV NSCLC

Goldman

Jenny Strunck (310) 794-3893

Tiger-1

Erlotinib (EGFR TKI) vs. Rociletinib (EGFR TKI)

EGFR+advanced NSCLC

Goldman

Jenny Strunck (310) 794-3893

TRIO-US L-05

Pemetrexed + AUY922 dose escalation

previously treated metastatic non-squamous NSCLC

Garon

Jenny Strunck (310) 794-3893